MCID: MLD018
MIFTS: 50

Mild Cognitive Impairment

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Mild Cognitive Impairment

MalaCards integrated aliases for Mild Cognitive Impairment:

Name: Mild Cognitive Impairment 11 75 41 14

Classifications:



External Ids:

Disease Ontology 11 DOID:0080832

Summaries for Mild Cognitive Impairment

MedlinePlus: 41 Some forgetfulness can be a normal part of aging. However, some people have more memory problems than other people their age. This condition is called mild cognitive impairment, or MCI. People with MCI can take care of themselves and do their normal activities. MCI memory problems may include: Losing things often Forgetting to go to events and appointments Having more trouble coming up with words than other people of the same age Memory problems can also have other causes, including certain medicines and diseases that affect the blood vessels that supply the brain. Some of the problems brought on by these conditions can be managed or reversed. Your health care provider can do thinking, memory, and language tests to see if you have MCI. You may also need to see a specialist for more tests. Because MCI may be an early sign of Alzheimer's disease, it's really important to see your health care provider every 6 to 12 months. At this time, there is no proven drug treatment for MCI. Your health care provider can check to see if you have any changes in your memory or thinking skills over time. NIH: National Institute on Aging

MalaCards based summary: Mild Cognitive Impairment is related to dementia and alzheimer disease, familial, 1. An important gene associated with Mild Cognitive Impairment is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are Alzheimer's disease and miRNA effects and Presenilin-Mediated Signaling. The drugs Metformin and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and globus pallidus, and related phenotypes are nervous system and homeostasis/metabolism

Disease Ontology: 11 A cognitive disorder that is characterized by objective impairment in cognition with minimal impairment of their capacity to undertake the instrumental activities of daily living.

Wikipedia: 75 Mild cognitive impairment (MCI) is a neurocognitive disorder which involves cognitive impairments beyond... more...

Related Diseases for Mild Cognitive Impairment

Diseases related to Mild Cognitive Impairment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 547)
# Related Disease Score Top Affiliating Genes
1 dementia 32.0 TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
2 alzheimer disease, familial, 1 31.9 TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
3 amyloidosis 31.9 SNCA SERPINA3 PSEN2 PSEN1 MAPT BACE1
4 cerebrovascular disease 31.6 SERPINA3 MIR181C MIR132 MAPT BDNF BACE1
5 anosognosia 31.6 PSEN2 PSEN1 MAPT APOE
6 rem sleep behavior disorder 31.5 SNCA MAPT BCHE APOE
7 sleep disorder 31.4 SNCA BDNF APOE
8 tremor 31.4 SNCA MAPT CNTN2
9 parkinson disease, late-onset 31.4 SNCA SERPINA3 PSEN2 PSEN1 NEFL MIRLET7D
10 parkinsonism 31.4 SNCA PSEN1 MAPT APP APOE
11 apnea, obstructive sleep 31.3 MIRLET7D BDNF APOE
12 subjective cognitive decline 31.3 TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
13 amnestic disorder 31.3 PSEN2 PSEN1 MAPT CHAT BDNF BCHE
14 movement disease 31.3 SNCA SERPINA3 PSEN2 PSEN1 NEFL MIR132
15 stroke, ischemic 31.2 SERPINA3 PSEN1 MAPT CHAT BDNF BACE1
16 vascular dementia 31.2 SNCA SERPINA3 PSEN2 PSEN1 NEFL MIR15B
17 down syndrome 31.0 SERPINA3 PSEN1 MAPT CHAT BDNF BACE1
18 arteries, anomalies of 31.0 SERPINA3 MIRLET7D MIR15B MIR132 APOE
19 alzheimer disease 2 31.0 SNCA SERPINA3 APP APOE
20 psychotic disorder 31.0 SERPINA3 PSEN1 MIRLET7D MIR132 BDNF APP
21 mood disorder 31.0 SERPINA3 MIRLET7D MIR132 BDNF
22 dementia, lewy body 31.0 TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
23 bipolar disorder 30.9 MIR132 MAPT BDNF APP APOE
24 alzheimer disease 19 30.9 SERPINA3 PSEN2 PSEN1 APP APOE
25 attention deficit-hyperactivity disorder 30.9 SNCA SERPINA3 MAPT BDNF BCHE APP
26 frontotemporal dementia 30.8 TREM2 SNCA SERPINA3 PSEN2 PSEN1 NEFL
27 essential tremor 30.8 SNCA MAPT BDNF
28 agraphia 30.8 PSEN2 MAPT APOE
29 epilepsy 30.8 MIR132 CNTN2 BDNF APP APOE ADRA2B
30 cerebral amyloid angiopathy, cst3-related 30.8 TREM2 SNCA SERPINA3 PSEN2 PSEN1 MAPT
31 hydrocephalus 30.8 SNCA SERPINA3 PSEN1 MAPT BDNF APP
32 alzheimer disease 10 30.7 MAPT APOE
33 binswanger's disease 30.7 MAPT APP APOE
34 arteriolosclerosis 30.7 SNCA SERPINA3 MAPT APP APOE
35 alzheimer disease 11 30.7 PSEN1 MAPT
36 aphasia 30.7 SNCA PSEN2 PSEN1 NEFL MAPT BDNF
37 choreatic disease 30.7 SNCA BDNF APP
38 cerebral degeneration 30.6 TREM2 SNCA SERPINA3 NEFL MAPT APP
39 multiple system atrophy 1 30.6 SNCA SERPINA3 NEFL MIR132 MAPT CHAT
40 huntington disease 30.6 SNCA SERPINA3 PSEN2 PSEN1 MIR132 MAPT
41 secondary progressive multiple sclerosis 30.6 SERPINA3 NEFL MIR15B MIR132
42 alzheimer disease 3 30.5 PSEN2 PSEN1 BACE1 APP APOE
43 prion disease 30.5 SNCA SERPINA3 PSEN2 PSEN1 MIR132 MAPT
44 normal pressure hydrocephalus 30.5 SNCA SERPINA3 PSEN2 PSEN1 NEFL MAPT
45 prosopagnosia 30.5 PSEN2 MAPT
46 creutzfeldt-jakob disease 30.5 SNCA SERPINA3 PSEN1 MAPT APP APOE
47 alzheimer disease 9 30.4 PSEN1 MAPT APOE
48 nominal aphasia 30.4 SNCA PSEN2 PSEN1 MAPT BCHE APOE
49 amyloidosis, hereditary, transthyretin-related 30.4 SNCA APP APOE
50 eye disease 30.4 SERPINA3 MIRLET7D MIR132 BDNF APP APOE

Graphical network of the top 20 diseases related to Mild Cognitive Impairment:



Diseases related to Mild Cognitive Impairment

Symptoms & Phenotypes for Mild Cognitive Impairment

MGI Mouse Phenotypes related to Mild Cognitive Impairment:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.1 APOE APP BACE1 BDNF CHAT CNTN2
2 homeostasis/metabolism MP:0005376 10.1 ADRA2B APOE APP BACE1 BCHE BDNF
3 normal MP:0002873 10.06 APP BACE1 BDNF CHAT MAPT NEFL
4 behavior/neurological MP:0005386 10 ADRA2B APOE APP BACE1 BDNF CHAT
5 no phenotypic analysis MP:0003012 9.97 APOE APP BACE1 BDNF MAPT MIRLET7D
6 integument MP:0010771 9.32 APOE APP BACE1 BDNF DGUOK MAPT
7 taste/olfaction MP:0005394 9.26 APOE BDNF MAPT SNCA

Drugs & Therapeutics for Mild Cognitive Impairment

Drugs for Mild Cognitive Impairment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
2
Simvastatin Approved Phase 4 79902-63-9 54454
3
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
4
Levodopa Approved Phase 4 59-92-7, 63-84-3 6047
5
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
6
Donepezil Approved Phase 4 120014-06-4 3152
7
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
8
Galantamine Approved Phase 4 357-70-0, 1953-04-4 9651
9
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
10
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
11
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
12
Rasagiline Approved Phase 4 136236-51-6 3052776
13
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
14
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
15
Cannabidiol Approved, Investigational Phase 4 13956-29-1 521372 644019
16
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
17
Lithium carbonate Approved Phase 4 554-13-2
18
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
19
Nortriptyline Approved Phase 4 72-69-5 4543
20
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
21
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
22
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
23
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
24
Levetiracetam Approved Phase 4 102767-28-2 441341 5284583
25
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537 59227
26
Amitriptyline Approved Phase 4 50-48-6 2160
27
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
28
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
29
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
30
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
31
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
32
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
33
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
34
Pramipexole Approved, Investigational Phase 4 104632-26-0, 104632-25-9, 104632-28-2 4885 119570 59868
35
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
36
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
37
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
38
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 60857
39
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
40
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
41
Topiramate Approved Phase 4 97240-79-4 5284627
42
Iodine Approved, Investigational Phase 4 7553-56-2 807
43
Huperzine A Approved, Experimental Phase 4 102518-79-6
44
Choline Approved, Nutraceutical Phase 4 62-49-7 305
45
Tramiprosate Investigational Phase 4 3687-18-1 1646
46
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
47
Corticosterone Experimental Phase 4 50-22-6 5753
48
Cadexomer iodine Experimental Phase 4 94820-09-4
49 Anticholesteremic Agents Phase 4
50 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 1071)
# Name Status NCT ID Phase Drugs
1 Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease Unknown status NCT04346862 Phase 4 Acetyl-L-carnitine hydrochloride 500mg;Placebo
2 Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients Unknown status NCT00842920 Phase 4 Simvastatin 60 mg;Placebo;Simvastatin 20 mg
3 Can Methylphenidate (Ritalin) Improve Memory and Attention in Mild Cognitive Impairment? A Combined Behaviour-EEG Study Unknown status NCT02326038 Phase 4 Methylphenidate
4 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
5 Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI) Unknown status NCT00306124 Phase 4 Levodopa
6 Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE) Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
7 Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study Unknown status NCT02190019 Phase 4
8 Effects of Vildagliptin, a DPP-4 Inhibitor, in Elderly Diabetic Patients With Mild Cognitive Impairment Completed NCT03819127 Phase 4 Vildagliptin 50 MG Oral Tablet;Metformin Pill
9 Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly Completed NCT01951118 Phase 4 Donepezil
10 Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age Completed NCT01902004 Phase 4 Escitalopram;Memantine;Placebo
11 Olfactory Deficits in Mild Cognitive Impairment as a Predictor of Improved Cognition on Donepezil Completed NCT01845636 Phase 4 Donepezil;Atropine
12 The Depression and Memory Trial Completed NCT02590874 Phase 4 Duloxetine;Placebo
13 Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment Completed NCT00446485 Phase 4 Ginkgo biloba standardized extract 24/6;Ginkgo Biloba standardized extract 24/6;placebo
14 Genomic Outcomes of Metformin Completed NCT02986659 Phase 4 Metformin;Placebo
15 The Efficacy and Safety of Qinggongshoutao Bolus for aMnestic Mild Cognitive Impairment: A 52- Week Randomized, Double-blind, Controlled,Three Arms, Multi-center Study Completed NCT02982603 Phase 4 Qinggongshoutao Bolus;Ginkgo Biloba Extract 761;Placebos
16 A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment Completed NCT00934375 Phase 4 Aricept (donepezil hydrochloride);placebo
17 Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI: a Randomized, Double-blind, Placebo-controlled Exploratory Study Completed NCT01046292 Phase 4 Ginkgo biloba
18 Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression Completed NCT01658228 Phase 4 Donepezil;Placebo;Citalopram;Venlafaxine
19 A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease Completed NCT01519271 Phase 4 Exelon Patch (rivastigmine transdermal system);Placebo Patches
20 Core Temperature During Cold Exposure in Persons With Tetraplegia Completed NCT01822535 Phase 4 Midodrine hydrochloride
21 A Pilot, Multiple Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Use of Methylphenidate for Cognitive and Behavioral Symptoms in Mild Cognitive Impairment and Dementia Completed NCT03811847 Phase 4 Methylphenidate Extended Release Oral Capsule
22 A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study Completed NCT01126424 Phase 4 Solifenacin;Oxybutynin;Placebo
23 A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI) Completed NCT00293176 Phase 4 Donepezil Hydrochloride;Placebo
24 A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy Completed NCT01497652 Phase 4 Rasagiline/Placebo;Rasagiline
25 Water-based Activity to Enhance Recall in Veterans: A Randomized Clinical Trial Recruiting NCT04296565 Phase 4
26 Randomized-Controlled Trial of Trazodone on Reducing Plasma sST2 Level and Neurodegeneration Progression in Patients With Amnestic Mild Cognitive Impairment and Obstructive Sleep Apnea Recruiting NCT05209035 Phase 4 Trazodone
27 Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Recruiting NCT04522739 Phase 4 Spironolactone;Placebo
28 Comparative Randomized Clinical Trial of the Efficacy of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment and APOE ε4 Carriers Recruiting NCT05022186 Phase 4 Cannabidiol Oil;Homotaurine
29 RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT) Active, not recruiting NCT05531591 Phase 4 Aripiprazole Augmentation;Bupropion Augmentation;Switch to bupropion;Lithium Augmentation;Switch to nortriptyline
30 Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in a Cohort of Patients With Mild Cognitive Impairment Active, not recruiting NCT05594355 Phase 4 TEBOFORTAN
31 Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia Active, not recruiting NCT03185208 Phase 4 Lithium Carbonate;Placebo oral capsule
32 Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia Active, not recruiting NCT02379156 Phase 4 Midodrine Hydrochloride
33 Myocardial 123I-MIBG Scintigraphy in Aging and Neurodegenerative Disease Enrolling by invitation NCT05514106 Phase 4 meta-iodobenzylguanidine (MIBG) (123I)
34 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
35 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
36 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
37 A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment(ESCALADE) Not yet recruiting NCT05041790 Phase 4 Choline Alfoscerate;Placebo
38 Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Not yet recruiting NCT02931136 Phase 4 Huperzine A;Placebo
39 A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Mild Cognitive Impairment Patients With Cerebrovascular Disease Not yet recruiting NCT05050604 Phase 4 Choline Alfoscerate 400mg;Placebo of Choline Alfoscerate 400mg
40 The Safety and Efficacy of 1612 Capsules in Treatment of aMnestic Mild Cognitive Impairment: a 52-week, Double Blind,Randomized, Parallel,Placebo Controlled Trial. Withdrawn NCT02982642 Phase 4 1612 capsule;Placebos
41 DIetary Supplements, Executive funcTions and Vitamin D (DIET-D): a Double-blind Randomized Controlled Trial Unknown status NCT01708005 Phase 2, Phase 3 Lecitone®Se-Vitamin D3;Placebo
42 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
43 Investigating the Efficacy of Ergothioneine to Delay Cognitive Decline in Mild Cognitively Impaired Subjects Unknown status NCT03641404 Phase 3
44 Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Study of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Subjects in Early Rehabilitation Period of Ischemic Stroke Completed NCT03815292 Phase 3 MMH-MAP;Placebo
45 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Completed NCT03682185 Phase 3
46 Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment Completed NCT01876823 Phase 2, Phase 3 es-citalopram;Memantine
47 Exercise Training to Improve Cognitive Function Completed NCT03824639 Phase 3
48 A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type Completed NCT03721705 Phase 3
49 Testosterone Supplementation in Men With MCI Completed NCT00539305 Phase 3 testosterone gel;placebo gel
50 The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder Completed NCT04318639 Phase 2, Phase 3

Search NIH Clinical Center for Mild Cognitive Impairment

Genetic Tests for Mild Cognitive Impairment

Anatomical Context for Mild Cognitive Impairment

Organs/tissues related to Mild Cognitive Impairment:

MalaCards : Brain, Temporal Lobe, Globus Pallidus, Prefrontal Cortex, Subthalamic Nucleus, Cortex, Heart

Publications for Mild Cognitive Impairment

Articles related to Mild Cognitive Impairment:

(show top 50) (show all 21817)
# Title Authors PMID Year
1
Classification of Alzheimer's disease stage using machine learning for left and right oxygenation difference signals in the prefrontal cortex: a patient-level, single-group, diagnostic interventional trial. 62 41
36394721 2022
2
Effects of Lactiplantibacillus plantarum OLL2712 on Memory Function in Older Adults with Declining Memory: A Randomized Placebo-Controlled Trial. 41
36296983 2022
3
Effect of Multimodal Intervention (computer based cognitive training, diet and exercise) in comparison to health awareness among older adults with Subjective Cognitive Impairment (MISCI-Trial)-A Pilot Randomized Control Trial. 41
36327345 2022
4
Proteomics of serum exosomes identified fibulin-1 as a novel biomarker for mild cognitive impairment. 62
36018182 2023
5
What Are the Key Diagnostic Cognitive Impairment and Dementia Subtypes and How to Integrate all of the Diagnostic Data to Establish a Diagnosis? 62
36404034 2023
6
Mild Cognitive Impairment: Diagnosis and Subtypes. 62
34549629 2023
7
Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report. 62
36388611 2023
8
Reduced power and phase-locking values were accompanied by thalamus, putamen, and hippocampus atrophy in Parkinson's disease with mild cognitive impairment: an event-related oscillation study. 62
36395544 2023
9
Machine Learning Model to Predict Diagnosis of Mild Cognitive Impairment by Using Radiomic and Amyloid Brain PET. 62
36240660 2023
10
Special Issue: Mild Cognitive Impairment. 62
36413419 2023
11
Frequency and correlates of mild cognitive impairment and dementia among the oldest old - Evidence from the representative "Survey on quality of life and subjective well-being of the very old in North Rhine-Westphalia (NRW80+)". 62
36084607 2023
12
Olfactory Function and Diffusion Tensor Imaging as Markers of Mild Cognitive Impairment in Early Stages of Parkinson's Disease. 62
34841903 2023
13
What a Single Electroencephalographic (EEG) Channel Can Tell us About Alzheimer's Disease Patients With Mild Cognitive Impairment. 62
36413420 2023
14
Cerebral vasomotor reactivity across the continuum of subjective cognitive impairment, amnestic mild cognitive impairment and probable Alzheimer's dementia: A transcranial Doppler and PET/MRI study. 62
36314070 2023
15
Standardization and Validation of the Flash Visual Evoked Potential-P2 Conversion Scores in the Diagnosis of Amnestic Mild Cognitive Impairment and Alzheimer's Dementia. 62
34994216 2023
16
EEG Resting-State Functional Networks in Amnestic Mild Cognitive Impairment. 62
35758261 2023
17
Neuroimaging-Guided Transcranial Magnetic and Direct Current Stimulation in MCI: Toward an Individual, Effective and Disease-Modifying Treatment. 62
34751037 2023
18
CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework. 62
36368195 2023
19
Social determinants of memory change: A three-year follow-up of the Canadian Longitudinal Study on Aging (CLSA). 62
36257162 2023
20
Cognitive stimulation and cognitive results in older adults: A systematic review and meta-analysis. 62
36116285 2023
21
Predicting time-to-conversion for dementia of Alzheimer's type using multi-modal deep survival analysis. 62
36442416 2023
22
Effectiveness of online-based cognitive intervention in community-dwelling older adults with cognitive dysfunction: A systematic review and meta-analysis. 62
36468299 2023
23
An explainable Artificial Intelligence approach to study MCI to AD conversion via HD-EEG processing. 62
34889152 2023
24
An efficient Alzheimer's disease prediction based on MEPC-SSC segmentation and momentum geo-transient MLPs. 62
36375415 2022
25
My Healthy Brain: Rationale and Case Report of a Virtual Group Lifestyle Program Targeting Modifiable Risk Factors for Dementia. 62
35079948 2022
26
Microstate feature fusion for distinguishing AD from MCI. 62
35911952 2022
27
Differences in Brain Volume by Tooth Loss and Cognitive Function in Older Japanese Adults. 62
35831211 2022
28
[Implementation and Effect of the Multimodal Psychosocial MAKS Intervention in Day Care Centers for People with Cognitive Impairment: Follow-up Results After the End of the RCT]. 62
34560797 2022
29
Altered retinal cerebral vessel oscillation frequencies in Alzheimer's disease compatible with impaired amyloid clearance. 62
36174284 2022
30
EEG markers and subjective memory complaints in young and older people. 62
36150529 2022
31
Cholesterol dysregulation in peripheral blood mononuclear cells of Alzheimer's disease. 62
36334319 2022
32
Is non-invasive brain stimulation effective for cognitive enhancement in Alzheimer's disease? An updated meta-analysis. 62
36215904 2022
33
Multi-label classification of Alzheimer's disease stages from resting-state fMRI-based correlation connectivity data and deep learning. 62
36423532 2022
34
Association of blood-based biomarkers with radiologic markers and cognitive decline in atrial fibrillation patients. 62
36309005 2022
35
Assessment of Alzheimer's Disease Imaging Biomarkers in World Trade Center Responders with Cognitive Impairment at Midlife. 62
36398306 2022
36
Mid- and Late-Life Physical Activity and Neuropsychiatric Symptoms in Dementia-Free Older Adults: Mayo Clinic Study of Aging. 62
36464975 2022
37
Associations among hypertension, dementia biomarkers, and cognition: The MEMENTO cohort. 62
36464896 2022
38
Convolutional Neural Networks-Based Framework for Early Identification of Dementia Using MRI of Brain Asymmetry. 62
36106446 2022
39
Wayfinding and spatial perception among adolescents with mild intellectual disability. 62
35510305 2022
40
Separation of memory span and learning rate: Evidence from behavior and spontaneous brain activity in older adults. 62
35922140 2022
41
A 5-year community program in Singapore to prevent cognitive decline. 62
35922040 2022
42
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer's Disease. 62
35960495 2022
43
A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease. 62
35965282 2022
44
Neuropsychiatric, neuropsychological, and neuroimaging features in isolated REM sleep behavior disorder: The importance of MCI. 62
36116292 2022
45
Efficacy of ICT-based interventions in improving psychological outcomes among older adults with MCI and dementia: A systematic review and meta-analysis. 62
36343879 2022
46
Apolipoprotein E genotype, inflammatory biomarkers, and non-psychiatric multimorbidity contribute to the suicidal ideation phenotype in older age. The Salus in Apulia Study. 62
36155237 2022
47
Surviving a 400 m Fall on Mount Everest. 62
36109266 2022
48
Brucellosis in older person: a case report from Qatar. 62
36286586 2022
49
Graphical methods for understanding changes in states: Understanding medication use pathways. 62
35894783 2022
50
Impact of constipation on progression of Alzheimer's disease: A retrospective study. 62
35934956 2022

Variations for Mild Cognitive Impairment

Expression for Mild Cognitive Impairment

Search GEO for disease gene expression data for Mild Cognitive Impairment.

Pathways for Mild Cognitive Impairment

GO Terms for Mild Cognitive Impairment

Cellular components related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.4 SNCA SERPINA3 MIRLET7D MIR181C MIR15B MIR132
2 early endosome GO:0005769 10.16 PSEN2 PSEN1 BACE1 APP APOE
3 membrane raft GO:0045121 10.13 PSEN2 PSEN1 MAPT BACE1 APP
4 neuron projection GO:0043005 10.06 PSEN1 NEFL MAPT CNTN2 CHAT APP
5 neuronal cell body GO:0043025 10 APOE BACE1 CNTN2 MAPT PSEN1 PSEN2
6 neuromuscular junction GO:0031594 9.97 APP NEFL PSEN1 PSEN2
7 synaptic vesicle GO:0008021 9.96 PSEN2 PSEN1 BDNF BACE1 APP
8 dendritic shaft GO:0043198 9.95 APP PSEN1 PSEN2
9 gamma-secretase complex GO:0070765 9.83 PSEN2 PSEN1
10 ciliary rootlet GO:0035253 9.8 PSEN2 PSEN1 APP
11 main axon GO:0044304 9.76 MAPT APP
12 growth cone GO:0030426 9.7 SNCA PSEN2 PSEN1 NEFL MAPT APP
13 axon GO:0030424 9.5 SNCA PSEN1 NEFL MAPT CNTN2 BDNF

Biological processes related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.27 PSEN1 MIR132 MAPT APP APOE
2 neuron projection development GO:0031175 10.16 MAPT CNTN2 APP APOE
3 protein processing GO:0016485 10.14 PSEN2 PSEN1 CNTN2 BACE1
4 memory GO:0007613 10.13 TREM2 PSEN1 MAPT BDNF
5 synapse organization GO:0050808 10.08 SNCA PSEN1 MAPT APP
6 cellular response to copper ion GO:0071280 10.04 SNCA BACE1 APP
7 membrane protein ectodomain proteolysis GO:0006509 10.03 BACE1 PSEN1 PSEN2
8 cellular response to amyloid-beta GO:1904646 10.01 TREM2 PSEN1 BACE1 APP
9 response to lead ion GO:0010288 9.97 MAPT BACE1 APP
10 regulation of neuronal synaptic plasticity GO:0048168 9.95 APOE CNTN2 SNCA
11 cellular response to manganese ion GO:0071287 9.94 BACE1 APP
12 Notch receptor processing GO:0007220 9.94 PSEN2 PSEN1
13 positive regulation of amyloid-beta clearance GO:1900223 9.93 TREM2 APOE
14 amyloid precursor protein catabolic process GO:0042987 9.93 PSEN2 PSEN1 BACE1
15 amyloid fibril formation GO:1990000 9.92 SNCA MAPT BACE1 APP
16 regulation of axon diameter GO:0031133 9.91 NEFL CNTN2
17 amyloid-beta metabolic process GO:0050435 9.91 PSEN2 PSEN1 BACE1
18 astrocyte activation involved in immune response GO:0002265 9.9 APP PSEN1
19 negative regulation of blood vessel endothelial cell migration GO:0043537 9.88 MIR15B MIR132 APOE
20 amyloid-beta formation GO:0034205 9.85 BACE1 PSEN1 PSEN2
21 negative regulation of neuron apoptotic process GO:0043524 9.85 APOE BDNF MIR15B MIR181C PSEN1 SNCA
22 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.81 APP PSEN1
23 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.8 MIR181C MIR15B MIR132
24 negative regulation of astrocyte activation GO:0061889 9.77 MIR181C TREM2
25 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.76 PSEN1 APP
26 positive regulation of amyloid fibril formation GO:1905908 9.73 PSEN1 APP APOE
27 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.62 PSEN1 APP
28 astrocyte activation GO:0048143 9.56 TREM2 PSEN1 MAPT APP
29 microglial cell activation GO:0001774 9.28 TREM2 SNCA MIR181C MAPT APP

Molecular functions related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta binding GO:0001540 9.76 TREM2 BCHE BACE1 APOE
2 aspartic endopeptidase activity, intramembrane cleaving GO:0042500 9.56 PSEN2 PSEN1
3 aspartic-type endopeptidase activity GO:0004190 9.35 PSEN2 PSEN1 BACE1
4 lipoprotein particle binding GO:0071813 9.1 TREM2 MAPT APOE

Sources for Mild Cognitive Impairment

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....